IRRITABLE BOWEL SYNDROME AND CBD; NEW CLINICAL TRIALS

IRRITABLE BOWEL SYNDROME AND CBD; NEW CLINICAL TRIALS

AXIM Biotechnologies, Inc., a leader of research in the industrial hemp industry will soon enter CBD clinical trials. These studies will find information about the effects of CBD on irritable bowel syndrome or IBS. All studies will occur in the Netherlands with a subject group of patients who suffer from IBS. Each will consume various doses of chewing gum with infused CBD, CanChew Plus.

The Study

Since the Medical Ethical Committee of Wageningen University gave approval for the research team to host a study on IBS symptoms, clinical trials with soon begin. In a control study, patients will chew 50mg of CBD at a time. Trials suggest that one can consume six pieces of gum a day.

The CBD clinical trial includes 40 IBS patients between the age of 18 and 65.

The Product

CanChew combines the daily activity of chewing gum with the need for a daily CBD dose. It seems like the idea of cannabinoids administered by chewing gum came about by nicotine-replacement gum. This means, CBD absorbs through the mucus membrane of the mouth, quickly, to provide effects long-term. CBD chewing gum is a delivery method has a patent by CanChew Plus. This technology provides constant administration of CBD for longer periods of time.

About IBS

According to aboutibs.org, IBS affects 25 to 24 million people in the United States. Yet the cause of IBS is not fully understood. Knowing how many people suffer from the symptoms, new treatment and studies need to be conducted. Symptoms are uncomfortable and can affect the way one lives their day-to-day life. Pain directly to the abdominal is the most noticeable symptoms with irregular bowel habits.

Other Common Symptoms of IBS

  • Bloating
  • Mucus
  • Bladder control

CBD and Irritable Bowel Syndrome

Through the CBD clinical trials, this cannabinoid shows promise to provide relief to patients who suffer from IBS. During the study, it is the mission bring awareness to cannabinoid solution to not only IBS but also; Crohn’s disease, inflammatory bowel disease and other health conditions.

“IBS is a very common and often painful disorder which is still difficult to manage. People often experience sudden flare-ups and for many it has a negative impact on their quality of life. CBD has shown to have promising effects, but there has been a clear need for practical and effective formulations,” said Renger Witkamp, Professor and Chair in Nutrition and Pharmacology of Wageningen University.

Finding quality and informative research is top priority for the research team and Wageningen University. The University is a world-class institution that provides top-notch education in life, environmental and agricultural sciences. This study at Wageningen University will be the first of its kind, where IBS treatment is with cannabinoids.